Biosplice Therapeutics, Inc.
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT05603754
- Locations
- 🇺🇸
Eastern Research, Inc., Hialeah, Florida, United States
🇺🇸TecTum Research, Hollywood, Florida, United States
🇺🇸Conquest Research, LLC, Winter Park, Florida, United States
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05084859
- Locations
- 🇺🇸
Duke Cancer Institute (DCI) - Duke Cancer Center, Durham, North Carolina, United States
🇺🇸UT Health San Antonio - Mays Cancer Center - Institute for Drug Development, San Antonio, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04931667
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04598542
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT04520607
- Locations
- 🇺🇸
Research Site, Charlottesville, Virginia, United States
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04385303
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
🇺🇸Research Site 1, Saint Louis, Missouri, United States
🇺🇸Research Site 2, Saint Louis, Missouri, United States
A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 513
- Registration Number
- NCT03928184
- Locations
- 🇺🇸
Research Site #1, Winter Park, Florida, United States
🇺🇸Research Site 2, New York, New York, United States
🇺🇸Research Site, Richmond, Virginia, United States
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 675
- Registration Number
- NCT03742518
- Locations
- 🇹🇷
Research Site 1, Trabzon, Turkey
🇹🇷Research Site, Samsun, Turkey
🇹🇷Research Site 2, Trabzon, Turkey
A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03727022
- Locations
- 🇺🇸
Research Site, San Angelo, Texas, United States
A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03706521
- Locations
- 🇺🇸
Research Site, San Francisco, California, United States